Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model | Zendy

Carin A. Uylde Groot | Zendy; Joseph McDonnell | Zendy; Guul ten Velde | Zendy; David Radice | Zendy; Harry J.M. Groen | Zendy

Open Access

Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model

Author(s) -

Carin A. Uylde Groot,

Joseph McDonnell,

Guul ten Velde,

David Radice,

Harry J.M. Groen

Publication year - 2006

Publication title -

therapeutics and clinical risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.719

H-Index - 55

eISSN - 1178-203X

pISSN - 1176-6336

DOI - 10.2147/tcrm.2006.2.3.317

Subject(s) - medicine , etoposide , lung cancer , quality of life (healthcare) , cisplatin , modalities , oncology , quality adjusted life year , health care , cost effectiveness , intensive care medicine , chemotherapy , risk analysis (engineering) , social science , nursing , sociology , economics , economic growth

In the last decade, a number of new treatment modalities have been developed for patients with small cell lung cancer (SCLC). The clinical effects are encouraging, but little is known about the costs and cost-effectiveness of new drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research